ライフサイエンスコーパス: topoisomerase

1 ial growth and low homology with other human topoisomerases.

2 ne interactions with other bacterial type II topoisomerases.

3 supercoiled DNA to nicking endonucleases and topoisomerases.

4 romoter and the temporal expression of three topoisomerases.

5 nalyzed three putative Chlamydia trachomatis topoisomerases.

6 d, most have not been tested with respect to topoisomerases.

7 o be regulated by a family of enzymes called topoisomerases.

8 mode-of-inhibition against bacterial type II topoisomerases.

9 he transcription machinery directly controls topoisomerase 1 (TOP1) activity to adjust DNA topology t

10 We identified topoisomerase 1 (Top1) as a positive regulator of RNA po

11 fied depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and

12 nition 1 (Nsr1) and its interacting partner, topoisomerase 1 (Top1), are polyphosphorylated.

13 ed proteins that function in RNA metabolism (Topoisomerase 1 and RNA helicases), DNA repair/replicati

14 We also identified topoisomerase 1 as a cardinal Aire partner that colocali

15 ous SSc with pulmonary fibrosis and anti-DNA topoisomerase 1 autoantibodies.

16 hypomorphic mice accumulate DPCs containing Topoisomerase 1 covalently linked to DNA.

17 encing (ChIP-seq) versus TOP1 activity using topoisomerase 1 sequencing (TOP1-seq), a method reported

18 RNA polymerase II is increased, and that of topoisomerase 1, an R-loop preventing factor, is decreas

19 Eukaryotic topoisomerase 2 (Top2) and one of its interacting partne

20 Topoisomerase 2 (TOP2) DNA transactions proceed via form

21 osyl-DNA phosphodiesterase 2 (Tdp2) reverses Topoisomerase 2 (Top2) DNA-protein crosslinks triggered

22 c acid processing enzymes, in particular DNA topoisomerase 2 (TOP2).

23 promote DNA breaks via its interaction with topoisomerase 2 (TOP2).

24 ether with the downregulation of its target, Topoisomerase 2 alpha (TOP2A), in glioma cell lines, res

25 vant as Hat1-/- cells are hyper-sensitive to topoisomerase 2 inhibition suggesting that Hat1 is requi

26 The enrichment of topoisomerase 2 is functionally relevant as Hat1-/- cell

27 chromosomal DSBs and extreme sensitivity to topoisomerase 2 poisons.

28 echanistically, ARID1A deficiency results in topoisomerase 2A and cell cycle defects, which cause an

29 Hat1-/- nascent chromatin is enriched for topoisomerase 2alpha and 2beta.

30 DNA double strand breaks (DSBs) mediated by topoisomerase 2B (TOP2B).

31 rt that D loops can also be disrupted by DNA topoisomerase 3 (Top3), and this disruption depends on T

32 gion sharing high homology with DDR proteins Topoisomerase 3alpha (TOP3alpha) and NEIL3 (Nei-like DNA

33 emonstrate that the mitochondrial isoform of topoisomerase 3alpha (Top3alpha) fulfills this function,

34 Topoisomerase 3beta (Top3beta) can associate with the me

35 elicase, a type IB topoisomerase, a type IIA topoisomerase, a non-specific mitochondrial DNA binding

36 pendent DNA binding of a helicase, a type IB topoisomerase, a type IIA topoisomerase, a non-specific

37 have revealed unexpected roles of type I DNA topoisomerases, a subclass of these enzymes, in regulati

38 referentially occur in contexts that inhibit topoisomerase action ahead of the fork, including stable

39 sms, including intra-chromosomal compaction, topoisomerase action and Holliday junction resolvases, e

40 ain is a mystery that requires rethinking of topoisomerase action around polymerases.

41 erichia coli DNA topoisomerase I has low RNA topoisomerase activity and that the R173A point mutation

42 Unexpectedly, the topoisomerase activity is compromised by K391/K436 SUMOy

43 The topoisomerase activity is conferred by a small alpha-hel

44 Here, we show that RNA topoisomerase activity is prevalent in Type IA topoisome

45 benzimidazoles (3, 6, 7, 8) also inhibit RNA topoisomerase activity of E. coli DNA topoisomerase I.

46 The RNA topoisomerase activity of human Top3beta differs from th

47 f endogenous lesions may arise from aberrant topoisomerase activity or ribonucleotide incorporation i

48 only known topoisomerase that possesses RNA topoisomerase activity, binds mRNA translation machinery

49 low potency for inhibition of human type II topoisomerases alpha and beta.

50 ng studies of a 97 kDa fragment spanning the topoisomerase and 10 (HhH)2 domains reveal that the (HhH

51 (Topo-V) is the only topoisomerase with both topoisomerase and DNA repair activities.

52 It has been reported that the absence of Topoisomerase and RNase H activity in Escherichia coli o

53 the topological conversion catalysed by DNA topoisomerase and to study the DNA replication under top

54 antibacterials that kill cells by inhibiting topoisomerases and inducing double-stranded DNA breaks.

55 lution between the nuclear and mitochondrial topoisomerases and potential cancer predisposition.

56 tegy that can be applied to study additional topoisomerases and their inhibitors in vitro and in vivo

57 he coordinated action of multiple nucleases, topoisomerases, and helicases.

58 s focused on the biological functions of DNA topoisomerases, and several findings have revealed unexp

59 in addition to its role in DNA repair, this topoisomerase antagonizes CO formation.

60 Bacterial topoisomerases are attractive antibacterial drug targets

61 Bacterial DNA topoisomerases are essential for bacterial growth and ar

62 DNA Topoisomerases are essential to resolve topological prob

63 These new findings highlight that type I topoisomerases are still interesting targets for drug di

64 We propose that RNA topoisomerases arose in the early RNA world, and that th

65 le out interaction with DNA or inhibition of topoisomerase, both of which are common modes of action

66 Type IB DNA topoisomerases can eliminate torsional stresses produced

67 DNA topoisomerases constitute a large family of enzymes that

68 Top3beta, but not other topoisomerases, contains a distinctive RNA-binding domai

69 In cells lacking Tdp1, clearance of topoisomerase covalent complexes becomes SUMO and Wss1-d

70 Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both

71 opyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display

72 Fluoroquinolones form drug-topoisomerase-DNA complexes that rapidly block transcrip

73 mode not evident in X-ray structures of drug-topoisomerase-DNA complexes.

74 that the (HhH)2 domains extend away from the topoisomerase domain.

75 ndrial topoisomerase I (TOP1MT) is a type IB topoisomerase encoded in the nucleus of vertebrate cells

76 lass of antibiotics, which targets bacterial topoisomerases, fails to kill bacteria that have grown t

77 us and cytoplasm, but which one is the major topoisomerase for mRNAs is unclear.

78 Our data suggest that Top3beta is the major topoisomerase for mRNAs, and requires both RNA binding a

79 entary opportunities for targeting bacterial topoisomerases for antibiotic development.

80 poisomerase activity is prevalent in Type IA topoisomerases from bacteria, archaea, and eukarya.

81 inhibition of Neisseria gonorrhoeae type II topoisomerases gyrase and topoisomerase IV by AZD0914 (A

82 lysis of gyrase B of the beta subunit of DNA topoisomerase (gyrB), and 16S rRNA and subunit A of SecA

83 the latter requires the CTD, indicating that topoisomerases have developed distinct mechanisms during

84 wever, the activities and the roles of these topoisomerases have remained an open question.

85 Historically, type II topoisomerases have yielded clinically useful drugs for

86 These deletion events are dependent on DNA topoisomerase I (Top1) and are initiated by Top1 incisio

87 Ribonuclease activity of topoisomerase I (Top1) causes DNA nicks bearing 2',3'-cy

88 The topoisomerase I (TOP1) inhibitor irinotecan triggers cel

89 Camptothecin (CPT), a topoisomerase I (TOP1) inhibitor, exhibits anti-tumor ac

90 Indenoisoquinoline topoisomerase I (Top1) inhibitors are a novel class of a

91 The 7-azaindenoisoquinolines are cytotoxic topoisomerase I (Top1) inhibitors.

92 ccharomyces cerevisiae, become unstable when topoisomerase I (Top1) is disrupted.

93 ow rapid recruitment, within minutes, of DNA topoisomerase I (TOP1) to a large cohort of AR-regulated

94 transcription-associated damage in yeast is Topoisomerase I (Top1), an enzyme that removes torsional

95 ver, in a RNase H2 knock-out yeast strain, a topoisomerase I (Top1)-dependent mutator effect develops

96 Mitochondrial topoisomerase I (TOP1MT) is a type IB topoisomerase enco

97 Escherichia coli topoisomerase I (TopA), a regulator of global and local

98 mary cellular target of YjhX was found to be topoisomerase I (TopA), inhibiting both DNA replication

99 cancer drugs slow the religation step of DNA topoisomerase I (topo I).

100 nteraction between the C-terminal domains of topoisomerase I (TopoI-CTDs) and the beta' subunit of RN

101 In addition, the described ligand displayed topoisomerase I activity inhibition and self-fluorescenc

102 e of the protein-protein interaction between topoisomerase I and RNA polymerase during stress respons

103 The functional interaction between topoisomerase I and RNA polymerase has evolved independe

104 a distinct mechanism of interaction between topoisomerase I and RNA polymerase in Mycobacterium tube

105 characterized interaction between bacterial topoisomerase I and RNA polymerase.

106 consistent with negative feedback control of topoisomerase I and topoisomerase IV expression, which i

107 PB1 alleles using DNA obtained from 318 anti-topoisomerase I antibody-positive patients and 561 healt

108 These C-terminal domains of E. coli topoisomerase I are known to interact with RNA polymeras

109 YjhX inhibits only topoisomerase I but not topoisomerase III and IV in vitr

110 biomarkers such as carbonic anhydrase IX and topoisomerase I by immunohistochemistry show clear evide

111 rved in other previously available bacterial topoisomerase I crystal structures.

112 The DNA topoisomerase I enzyme of Mycobacterium tuberculosis (Mt

113 features observed for MtTOP1 may allow these topoisomerase I enzymes to carry out physiological funct

114 in M. smegmatis competed with the endogenous topoisomerase I for protein-protein interactions with RN

115 cal probe, we find that Escherichia coli DNA topoisomerase I has low RNA topoisomerase activity and t

116 p3beta differs from that of Escherichia coli topoisomerase I in that the former but not the latter re

117 rDNA and clarifies a structural role of DNA topoisomerase I in the epigenetic regulation of rDNA, in

118 ction by either transcription termination or topoisomerase I inhibition has been shown to increase pa

119 ochondrial inhibitors, intracellular ROS, or topoisomerase I inhibition orchestrates an inflammatory

120 yl side chains display excellent E. coli DNA topoisomerase I inhibition properties with IC50 values <

121 n synthesized and their Escherichia coli DNA topoisomerase I inhibition, binding to B-DNA duplex, and

122 Although the topoisomerase I inhibitor camptothecin also activated AT

123 nd PRC2 exhibit synthetic sensitivity to the topoisomerase I inhibitor Camptothecin and accumulate ga

124 This system contains SN-38-a prodrug of the topoisomerase I inhibitor irinotecan.

125 HER2, a novel enzyme-cleavable linker, and a topoisomerase I inhibitor payload.

126 n the present studies, an indenoisoquinoline topoisomerase I inhibitor was conjugated to DUPA via a p

127 p synthesis of a series of clinically active topoisomerase I inhibitors such as NSC 314622, LMP-400,

128 Topoisomerase I is a vital enzyme that controls DNA topo

129 An elevated level of topoisomerase I is found in many carcinomas, making it a

130 Bacterial DNA topoisomerase I is responsible for preventing the hyper-

131 mutations in ribonuclease H, senataxin, and topoisomerase I that resolve RNA-DNA hybrids lead to inc

132 The association of topoisomerase I with RNA polymerase during transcription

133 NA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter al

134 o subunits of DNA gyrase, whereas CT643 is a topoisomerase I.

135 n the C-terminal domains of Escherichia coli topoisomerase I.

136 st endogenous protein inhibitor specific for topoisomerase I.

137 it RNA topoisomerase activity of E. coli DNA topoisomerase I.

138 in and amino acids of the active site of DNA topoisomerase I.

139 Here we encapsulated the topoisomerase-I inhibitor SN-38 in polymeric nanoparticl

140 of scleroderma induced by immunization with topoisomerase-I peptide-loaded dendritic cells, Mehta et

141 establish the optimal nitrogen position for topoisomerase IB (Top1) enzyme poisoning activity and cy

142 3-Nitroindenoisoquinoline human topoisomerase IB (Top1) poisons have potent antiprolifer

143 Mitochondrial topoisomerase IB (TOP1MT) facilitates mtDNA replication

144 emperature, making it the first thermophilic topoisomerase IB characterized so far.

145 ll available thaumarchaeal genomes contain a topoisomerase IB gene that defines a monophyletic group

146 This newly described thermostable topoisomerases IB should be a promising new model for ev

147 ble-strand breaks (DSBs) induced by abortive topoisomerase II (TOP2) activity are a potential source

148 y.DNA double-strand breaks (DSBs) induced by topoisomerase II (TOP2) are rejoined by TDP2-dependent n

149 ng 5'-tyrosyl DNA adducts formed by abortive topoisomerase II (Top2) cleavage complexes to allow erro

150 For instance, topoisomerase II (Top2) is critically important for reso

151 DNA topoisomerase II (TOP2) plays a pivotal role in faithful

152 specifically repairs DNA damages induced by topoisomerase II (Top2) poisons and causes resistance to

153 nd immature myeloid cells and transforms the topoisomerase II (TOP2) poisons etoposide and mitoxantro

154 Here, we investigated the processing of topoisomerase II (Top2)-DNA adducts induced by treatment

155 sensitive measurements of the life essential topoisomerase II (Topo II) enzyme activity.

156 olecular target of resveratrol is eukaryotic topoisomerase II (topo II), an enzyme essential for chro

157 of doxorubicin was not due to inhibition of topoisomerase II (Topo II).

158 , chromosomes present high levels of de novo Topoisomerase II (TopoII)-dependent re-entanglements, an

159 ce to anaphase, suggesting the importance of topoisomerase II activity for proper chromosome condensa

160 icated that XWL-1-48 significantly inhibited topoisomerase II activity in a concentration-dependent m

161 The inhibition of topoisomerase II activity using specific inhibitors reve

162 nly used chemotherapeutic drug that inhibits topoisomerase II activity, thereby leading to genotoxici

163 l elongation-coupled DDR signalling involves topoisomerase II because inhibiting this enzyme interfer

164 Topoisomerase II beta (TOP2B) facilitates rapid gene exp

165 d by new insights that anthracycline targets topoisomerase II beta to cause DNA double-strand breaks

166 s should be based on inhibiting or degrading topoisomerase II beta.

167 pattern indicates the active requirement of topoisomerase II during these stages of the cell cycle.

168 KEY MESSAGE: The topoisomerase II expression varies as a function of cell

169 Maximal topoisomerase II expression was tightly coupled to S pha

170 cell cultures were used to study the role of topoisomerase II in various stages of the cell cycle.

171 Thus, XWL-1-48 may be a promising orally topoisomerase II inhibitor for treatment of HCC.

172 vative, XWL-1-48, was synthesized as an oral topoisomerase II inhibitor.

173 Contrary, topoisomerase II is not the major component of meiotic c

174 Even if topoisomerase II is required for individualization and c

175 Topoisomerase II is similarly required for linear chromo

176 he immuno-staining analysis also showed that topoisomerase II is the major component of mitotic chrom

177 r inter-sister homologous recombination, and topoisomerase II plays a role in generating the damage.

178 e, and change the mechanism of action from a topoisomerase II poison to a DNA cross-linker.

179 are selectively resistant to treatment with topoisomerase II poisons but not other DNA damaging agen

180 Topoisomerase II transcript accumulation was observed du

181 Through immuno-localization of topoisomerase II was observed diffusely throughout the n

182 ty to 12% of the tested compounds, including topoisomerase II, B-cell chronic lymphocytic leukemia/ly

183 tinostat and doxorubicin treatment inhibited topoisomerase II-beta (TopoII-beta) and relieved TopoII-

184 s and found that NONO favours the loading of topoisomerase II-binding protein 1 acting upstream of th

185 novel mechanism involving TRIM28, DNA-PK and topoisomerase II.

186 riant CENP-A and the DNA decatenizing enzyme topoisomerase-II (topo-II) as candidate modulators of ch

187 tumors displayed an enhanced response to the topoisomerase-II poison etoposide.

188 sensitivity to anthracyclines by recruiting topoisomerase IIa (TOP2A) to DNA and increasing double-s

189 gg extract, we found that SUMOylation of DNA topoisomerase IIalpha (TOP2A) CTD regulates the localiza

190 Topoisomerase IIalpha (TOP2A) has been proposed to resol

191 Among them, the gene encoding topoisomerase IIalpha (TOP2A) is commonly altered at bot

192 Topoisomerase IIalpha (TOP2alpha) is essential for chrom

193 ence that the C-terminal domain (CTD) of DNA topoisomerase IIalpha (Topo II) provides a novel functio

194 DNA topoisomerase IIalpha (Topo IIalpha) ensures genomic int

195 The data presented herein characterize topoisomerase IIalpha (TopoIIalpha) as a required compon

196 Interestingly, PICH also bound to SUMOylated topoisomerase IIalpha (TopoIIalpha), a major centromeric

197 chromosomes during meiosis, localization of topoisomerase IIalpha to bivalents was not affected; how

198 have fit poorly into the N-gate of the human topoisomerase IIalpha.

199 st proteins identified by mass spectrometry, topoisomerases IIalpha and IIbeta and PCNA were notewort

200 potential roles of host proteins, including topoisomerases IIalpha and IIbeta and PCNA, which were f

201 cted role for the cutting of promoter DNA by topoisomerase IIB to facilitate transcription of activit

202 es showed that Ku70/86 and components of the topoisomerase IIbeta (TOP2beta)/poly(ADP ribose) polymer

203 at Beclin 1 could directly interact with DNA topoisomerase IIbeta and was recruited to the DSB sites

204 (Top2) and one of its interacting partners, topoisomerase IIbeta binding protein 1 (TopBP1) are two

205 Topoisomerase IIbeta-binding protein 1 (TOPBP1) particip

206 YjhX inhibits only topoisomerase I but not topoisomerase III and IV in vitro.

207 out physiological functions associated with topoisomerase III enzyme in other bacteria.

208 Also, the human Topoisomerase IIIa-RMI1-RMI2 complex is capable of disso

209 3beta is also the most abundant mRNA-binding topoisomerase in cells.

210 Comparison with a type IB topoisomerase in similar experiments highlighted a relat

211 Human cells contain five topoisomerases in the nucleus and cytoplasm, but which o

212 In this study, we investigated topoisomerase-induced DNA breaks and chromatin structura

213 ain the synthetic lethality observed between topoisomerase-induced DNA breaks and the RecBCD gene pro

214 h its dual action as an alkylating agent and topoisomerase inhibitor, represents a novel anti-cancer

215 s that can repair damaged DNA resulting from topoisomerase inhibitors and a variety of other DNA-dama

216 mulin, a pleuromutilin, and new nonquinolone topoisomerase inhibitors are attractive possibilities th

217 Topoisomerase inhibitors are in common use as chemothera

218 Combinations of topoisomerase inhibitors I and II have been found to syn

219 ls more susceptible to cell death induced by topoisomerase inhibitors in an oncology drug screening a

220 Therefore, topoisomerase inhibitors regulate SAMHD1 and HIV permiss

221 lung cancer cells are largely insensitive to topoisomerase inhibitors, and depletion of PKCdelta can

222 -Ras-independent cells are more sensitive to topoisomerase inhibitors, and depletion of PKCdelta in t

223 antly, we demonstrate that DNA damage drugs, topoisomerase inhibitors, can trigger CKI activation to

224 We report that DNA damage induced by topoisomerase inhibitors, including etoposide (ETO), res

225 cells to be more sensitive to type I and II topoisomerase inhibitors, Raf inhibitors, and other drug

226 othetically potentiate the cytotoxicities of topoisomerase inhibitors.

227 tigated toxicological issues often seen with topoisomerase inhibitors.

228 This topoisomerase is being pursued as a novel target for the

229 Promoter analysis showed that each topoisomerase is transcribed from its own operon by the

230 fore they undergo a complete decatenation by topoisomerase IV (Topo IV).

231 n with ori, and limiting the availability of topoisomerase IV (TopoIV) at ter.

232 In bacteria, DNA gyrase and topoisomerase IV act ahead of the fork to keep DNA under

233 Topoisomerase IV also was able to distinguish DNA geomet

234 ng sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotic

235 onorrhoeae type II topoisomerases gyrase and topoisomerase IV by AZD0914 (AZD0914 will be henceforth

236 These findings suggest that the MukB-topoisomerase IV complex may provide a scaffold for DNA

237 Bacterial DNA gyrase and topoisomerase IV control the topological state of DNA du

238 caffold against the N-terminal domain of the topoisomerase IV E subunit from Escherichia coli (eParE)

239 ncodes a protein that does not interact with topoisomerase IV exhibit severe nucleoid decompaction le

240 tive feedback control of topoisomerase I and topoisomerase IV expression, which is typical of other b

241 tion of Staphylococcus aureus DNA gyrase and topoisomerase IV from both bacteria.

242 he most balanced inhibitor of DNA gyrase and topoisomerase IV from both E. coli and S. aureus.

243 ibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-positive and a Gram-nega

244 ed with negatively supercoiled) DNA, whereas topoisomerase IV generated similar levels with both subs

245 Although bacterial gyrase and topoisomerase IV have critical interactions with positiv

246 ased optimization toward dual DNA gyrase and topoisomerase IV inhibitors with antibacterial activity.

247 in MukB and the cellular decatenating enzyme topoisomerase IV interact.

248 We show here that the MukB-topoisomerase IV interaction stabilizes MukB on DNA, inc

249 rmation for further developing drugs against topoisomerase IV targets.

250 us anthracis and Escherichia coli gyrase and topoisomerase IV to relax and cleave positively supercoi

251 s indicate that gyrase is better suited than topoisomerase IV to safely remove positive supercoils th

252 positive supercoiling behind the fork where topoisomerase IV would also act to maintain replicating

253 erial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent activity against Gram-p

254 the target proteins, GyrA (gyrase) and ParC (topoisomerase IV).

255 are potent inhibitors of both DNA gyrase and topoisomerase IV, displaying antibacterial activities ag

256 ulates intramolecular reactions catalyzed by topoisomerase IV, supercoiled DNA relaxation, and DNA kn

257 t does not require the catalytic activity of topoisomerase IV.

258 indicating that the proteins are subunits of topoisomerase IV.

259 e ATP binding pockets of both DNA gyrase and topoisomerase IV.

260 e DNA helicase might overcome DNA gyrase and topoisomerase IV.

261 leaved complex for N. gonorrhoeae gyrase and topoisomerase IV.

262 st DNA gyrase from Staphylococcus aureus and topoisomerases IV from E. coli and S. aureus were determ

263 eated by Spo11, the evolutionarily conserved topoisomerase-like protein, but how these DSBs are distr

264 ed Actinobacteria, this subfamily of type IA topoisomerase may be required for multiple functions in

265 ll, Canela et al. (2017) reveal that type II topoisomerase-mediated release of torsional strain at ch

266 of topological enzymes such as type I and II topoisomerase, most of these defects can be avoided and

267 104) or absence (n = 49) of gyrA and/or parC topoisomerase mutations, qnrA, qnrB, qnrD, qnrS, aac(6')

268 Inhibiting topoisomerases or depleting histone chaperones increased

269 Type II topoisomerases orchestrate proper DNA topology, and they

270 Topoisomerases play crucial roles in DNA replication, tr

271 but not the final bicyclopentadione) mediate topoisomerase poisoning and possibly many other activiti

272 sublethal genotoxic treatments, using other topoisomerase poisons, DNA synthesis inhibitors, interst

273 DNA gyrase is a DNA topoisomerase present in bacteria and plants but not ani

274 Since there is only one type IA topoisomerase present in Mycobacteriaceae and related Ac

275 n pocket between the winged helix domain and topoisomerase-primase domain, remote from the DNA.

276 Surprisingly, all three topoisomerase promoters had higher activity from a more

277 o deficient in binding mRNAs, catalyzing RNA topoisomerase reaction, and promoting synapse formation.

278 s and the same catalytic residue used in DNA topoisomerase reaction; however, it does not absolutely

279 mechanisms during evolution to catalyze RNA topoisomerase reactions.

280 However, the prevalence and function of RNA topoisomerases remain uncertain.

281 p1 proteins, a histone deacetylase and a DNA topoisomerase, respectively, we investigated whether gen

282 interactors-including cohesins, condensins, topoisomerases, RNA helicases, chromatin remodelers, and

283 To date, Top3beta is the only known topoisomerase that possesses RNA topoisomerase activity,

284 Bacterial gyrases are a class of type II topoisomerases that can introduce negative supercoiling

285 he mechanism of genome regulation by type IA topoisomerases that is essential for life, as well as th

286 These DSBs are generated by type 2 topoisomerase to relieve topological constrains that lim

287 ed through transient DNA fracture by type II topoisomerases to permit chromosome segregation during c

288 In contrast to the other five human topoisomerases, TOP1MT possesses two high frequency sing

289 Type II DNA topoisomerases (TOP2) regulate DNA topology by generatin

290 because of the intrinsic feature of type II topoisomerases (Top2) to simplify DNA topology.

291 Sgs1 can associate with type-I topoisomerase Top3 and its accessory factor Rmi1 to form

292 Topoisomerase (topo) IIalpha and IIbeta maintain genome

293 rone and etoposide and generated new type II topoisomerase (topoII) poisons.

294 In the absence of the topoisomerase topoIV, the site-specific recombination co

295 Topoisomerase V (Topo-V) is the only topoisomerase with

296 Topoisomerase V (Topo-V) is the only topoisomerase with both topoisomerase and DNA repair act

297 more than one (HhH)2 domain, the only known topoisomerase with dual activities and is also unique by

298 The association of the topoisomerases with nascent DNA was dependent on express

299 d on cell and/or patient survival, including topoisomerases with RAD17 and checkpoint kinases with BL

300 model analogous to that observed for type IB topoisomerases, with religation probability varying in a